Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-21,000
Closed -$3.65M – 5235
2025
Q4
$3.65M Hold
21,000
– – ﹤0.01% 2469
2025
Q3
$3.02M Buy
+21,000
New +$2.57M ﹤0.01% 2558
2024
Q2
– Sell
-13,500
Closed -$366K – 5076
2024
Q1
$366K Buy
+13,500
New +$378K ﹤0.01% 3778
2019
Q4
– Sell
-1,600
Closed -$28K – 6561
2019
Q3
$28K Sell
1,600
-700
-30% -$13.5K ﹤0.01% 6129
2019
Q2
$59K Sell
2,300
-98,100
-98% -$2.73M ﹤0.01% 6015
2019
Q1
$2.92M Buy
100,400
+400
+0.4% +$10.4K ﹤0.01% 2161
2018
Q4
$1.31M Buy
+100,000
New +$1.6M ﹤0.01% 2836
2018
Q2
– Sell
-100
Closed -$2K – 7098
2018
Q1
$2K Buy
+100
New +$2.63K ﹤0.01% 6901
2017
Q4
– Sell
-81,800
Closed -$2.55M – 6999
2017
Q3
$2.55M Buy
81,800
+79,500
+3,457% +$1.51M ﹤0.01% 2110
2017
Q2
$39K Hold
2,300
– – ﹤0.01% 5484
2017
Q1
$40K Buy
+2,300
New +$35.5K ﹤0.01% 5459
2014
Q3
– Sell
-40,000
Closed -$760K – 7731
2014
Q2
$760K Sell
40,000
-195,400
-83% -$2.89M ﹤0.01% 3590
2014
Q1
$4.47M Buy
+235,400
New +$4.47M 0.01% 1776

Other funds holding INSM

Barclays's INSM Position: Q3 2026 in Review

Barclays reduced its Insmed (INSM) stake by 36% in Q3 2026, selling an estimated $7.87M and leaving 118,830 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1476.

Barclays first reported a position in INSM in Q2 2013 and has held it in 53 quarters since. The position peaked at $77.4M in Q4 2025. 705 funds tracked by Wall St. Rank hold INSM as of Q3 2026.

  • Barclays held 118,830 shares of Insmed worth $13.6M as of Q3 2026.
  • Barclays sold 66,813 Insmed shares in Q3 2026, an estimated $7.87M.
  • Insmed made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1476 holding.
  • Barclays first reported a position in Insmed in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Insmed position peaked at $77.4M in Q4 2025.
  • 705 funds tracked by Wall St. Rank held Insmed as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.